Drug Profile


Alternative Names: Autologous cardiac progenitor stem cell therapy - Celyad; Bone marrow derived mesenchymal cardiopoietic cells - Celyad; C-Cure; C3BR-CQR-1; C3BS-CQR-1; Congestive heart failure cardiopoietic regenerative therapy - Celyad

Latest Information Update: 12 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cardio3 BioSciences
  • Developer Celyad
  • Class Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Chronic heart failure

Most Recent Events

  • 11 May 2017 C3BS CQR 1 receives Fast track status from the US FDA for Chronic heart failure
  • 09 Sep 2016 Celyad completes the phase III CHART-1 trial in Chronic heart failure in Sweden, Ireland, Croatia, the United Kingdom, Belgium, Serbia, Bulgaria, Hungary, Spain, Italy, Poland, Switzerland and Israel
  • 28 Jun 2016 C3BS CQR 1 is available for licensing as of 28 Jun 2016. http://www.celyad.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top